Ever since 1929, the Academy Awards have honored some of our greatest cinematic performances and films—but they don’t always get it right. Welcome to the “snub club.” It’s a group of ...

Bipolar II disorder is a mental health condition that involves at least one depressive episode and at least one period of elevated mood, called hypomania. Bipolar II disorder causes intense ...

Alpha measures if a manager's skill, not luck, adds investment value beyond market returns. Understanding alpha helps investors avoid paying for market risk (beta) that can be managed ...

Alpha or Jensen Index (invented by Michael Jensen in the 1970s) is an index used in some financial models such as the capital asset pricing model (CAPM) to determine the highest possible return on an ...

Mobile Legends: Bang Bang fighter hero Alpha wreaks havoc on the battlefield together with his trusty companion, Beta. He possesses multiple crowd control effects and Lifesteal in his unique skill set ...

A joint Egyptian-British archaeological mission identified the tomb as belonging to King Thutmose II, an ancient Egyptian king who reigned sometime between 2000 and 1001 BC, the country’s ...

Factor II deficiency is a rare bleeding disorder. Symptoms can vary from mild to severe. It may be inherited or a result of other factors, such as medication disease or an autoimmune response.

Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.

2025 Non-GAAP EPS Guidance: $2.67 to $2.72, representing 11% to 13% growth. Bruker Corp (NASDAQ:BRKR) reported a strong Q4 2024 with a 14.6% year-over-year increase in revenues, reaching $979.6 ...

Good day, and welcome to the Bruker Corporation Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the ...

Bruker exceeded both EPS and revenue forecasts for Q4 2024. The company reported a 14.6% year-over-year increase in quarterly revenue. Stock price decreased by 0.77% despite the earnings beat ...